Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing–Based NTRK Fusion Detection in South Korea
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Tropomyosin receptor kinase (TRK) inhibitors are approved for the treatment of neurotrophic receptor tyrosine kinase (NTRK) fusion-positive tumors. The detection of NTRK fusion using a validated method is required before therapeutic application. An interlaboratory comparison study of next-generation sequencing (NGS)–based NTRK gene fusion detection with validated clinical samples was conducted at six major hospitals in South Korea. Materials and Methods A total of 18 samples, including a positive standard reference and eight positive and nine negative clinical samples, were validated using the VENTANA pan-TRK (EPR17341) and TruSight Oncology 500 assays. These samples were then tested using four different NGS panels currently being used at the six participating institutions. Results NTRK fusions were not detected in any of the nine negative clinical samples, demonstrating 100% specificity in all six participating institutions. All assays showed 100% analytical sensitivity to identify the NTRK fusion status in formalin-fixed paraffin-embedded (FFPE) samples, although with variable clinical sensitivity. False-negative results were due to low tumor purity, poor RNA quality, and DNA-based sequencing panel. The RNA-based targeted NGS assay showed an overall high success rate of identifying NTRK fusion status in FFPE samples. Conclusion This study is the first to test the proficiency of NGS-based NTRK detection in South Korea with the largest participating institutions. RNA-based NGS assays to detect NTRK fusions can accurately characterize fusion transcripts if sufficient RNA of adequate quality is available. The comparative performance data will support the implementation of targeted NGS-based sequencing assays for NTRK fusion detection in routine diagnostics.
Abstract
Purpose Tropomyosin receptor kinase (TRK) inhibitors are approved for the treatment of neurotrophic receptor tyrosine kinase (NTRK) fusion-positive tumors. The detection of NTRK fusion using a validated method is required before therapeutic application. An interlaboratory comparison study of next-generation sequencing (NGS)–based NTRK gene fusion detection with validated clinical samples was conducted at six major hospitals in South Korea. Materials and Methods A total of 18 samples, including a positive standard reference and eight positive and nine negative clinical samples, were validated using the VENTANA pan-TRK (EPR17341) and TruSight Oncology 500 assays. These samples were then tested using four different NGS panels currently being used at the six participating institutions. Results NTRK fusions were not detected in any of the nine negative clinical samples, demonstrating 100% specificity in all six participating institutions. All assays showed 100% analytical sensitivity to identify the NTRK fusion status in formalin-fixed paraffin-embedded (FFPE) samples, although with variable clinical sensitivity. False-negative results were due to low tumor purity, poor RNA quality, and DNA-based sequencing panel. The RNA-based targeted NGS assay showed an overall high success rate of identifying NTRK fusion status in FFPE samples. Conclusion This study is the first to test the proficiency of NGS-based NTRK detection in South Korea with the largest participating institutions. RNA-based NGS assays to detect NTRK fusions can accurately characterize fusion transcripts if sufficient RNA of adequate quality is available. The comparative performance data will support the implementation of targeted NGS-based sequencing assays for NTRK fusion detection in routine diagnostics.
참고문헌 (25)
- Vaishnavi A, "TRKing down an old oncogene in a new era of targeted therapy", Cancer Discov, 5, pp.25~34 (2015)
- Cocco E, "NTRK fusion-positive cancers and TRK inhibitor therapy", Nat Rev Clin Oncol, 15, pp.731~747 (2018)
- Okamura R, "Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics", JCO Precis Oncol, 2018 (2018)
- Federman N, "Larotrectinib, a highly selective tropomyosin receptor kinase(TRK)inhibitor for the treatment of TRK fusion cancer", Expert Rev Clin Pharmacol, 12, pp.931~939 (2019)
- Scott LJ, "Larotrectinib : first global approval", Drugs, 79, pp.201~206 (2019)
- Chen Y, "Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers", J Hematol Oncol, 11, pp.78~ (2018)
- Doebele RC, "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials", Lancet Oncol, 21, pp.271~282 (2020)
- Gatalica Z, "Molecular characterization of cancers with NTRK gene fusions", Mod Pathol, 32, pp.147~153 (2019)
- Hsiao SJ, "Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase(TRK)inhibitor therapy", J Mol Diagn, 21, pp.553~571 (2019)
- "FDA approves companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi" (2020)[URL]
- Hechtman JF, "Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions", Am J Surg Pathol, 41, pp.1547~1551 (2017)
- Solomon JP, "NTRK fusion detection across multiple assays and 33, 997 cases : diagnostic implications and pitfalls", Mod Pathol, 33, pp.38~46 (2020)
- Penault-Llorca F, "Testing algorithm for identification of patients with TRK fusion cancer", J Clin Pathol, 72, pp.460~467 (2019)
- Xu B, "Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3fusion", Histopathology, 76, pp.375~382 (2020)
- Bourgeois JM, "Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors", Am J Surg Pathol, 24, pp.937~946 (2000)
- Davis JL, "Infantile NTRK-associated mesenchymal tumors", Pediatr Dev Pathol, 21, pp.68~78 (2018)
- Rubin BP, "Congenital mesoblastic nephroma t(12;15)is associated with ETV6-NTRK3 gene fusion : cytogenetic and molecular relationship to congenital(infantile)fibrosarcoma", Am J Pathol, 153, pp.1451~1458 (1998)
- Skalova A, "Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene : a hitherto undescribed salivary gland tumor entity", Am J Surg Pathol, 34, pp.599~608 (2010)
- Tognon C, "Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma", Cancer Cell, 2, pp.367~376 (2002)
- Benayed R, "High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden", Clin Cancer Res, 25, pp.4712~4722 (2019)
- Solomon JP, "Detection of NTRK fusions : merits and limitations of current diagnostic platforms", Cancer Res, 79, pp.3163~3168 (2019)
- Haynes BC, "An integrated next-generation sequencing system for analyzing DNA mutations, gene fusions, and RNA expression in lung cancer", Transl Oncol, 12, pp.836~845 (2019)
- Pfarr N, "Testing NTRK testing : Wet-lab and in silico comparison of RNA-based targeted sequencing assays", Genes Chromosomes Cancer, 59, pp.178~188 (2020)
- von Ahlfen S, "Determinants of RNA quality from FFPE samples", PLoS One, 2, pp.e1261~ (2007)
- Kirchner M, "RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples", Cancers(Basel), 11, pp.1309~ (2019)